|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
18
|
|
pubmed:dateCreated |
2003-8-27
|
|
pubmed:abstractText |
A novel series of anilinopyrazoles has been designed based on the X-ray crystal structure analysis. Most compounds from this series not only show sub-nanomolar IC(50) values for CDK2, but also demonstrate almost 1000-fold selectivity to other kinases including CDK1.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
0960-894X
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
13
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2985-8
|
|
pubmed:dateRevised |
2009-11-19
|
|
pubmed:meshHeading |
pubmed-meshheading:12941317-Binding Sites,
pubmed-meshheading:12941317-CDC2-CDC28 Kinases,
pubmed-meshheading:12941317-Crystallography, X-Ray,
pubmed-meshheading:12941317-Cyclin-Dependent Kinase 2,
pubmed-meshheading:12941317-Drug Design,
pubmed-meshheading:12941317-Enzyme Inhibitors,
pubmed-meshheading:12941317-Humans,
pubmed-meshheading:12941317-Inhibitory Concentration 50,
pubmed-meshheading:12941317-Models, Molecular,
pubmed-meshheading:12941317-Protein Binding,
pubmed-meshheading:12941317-Pyrazoles,
pubmed-meshheading:12941317-Structure-Activity Relationship
|
|
pubmed:year |
2003
|
|
pubmed:articleTitle |
Anilinopyrazole as selective CDK2 inhibitors: design, synthesis, biological evaluation, and X-ray crystallographic analysis.
|
|
pubmed:affiliation |
GlaxoSmithKline K. K. Tsukuba Research Laboratories, 43 Wadai Tsukuba, Ibaraki 300-4247, Japan. jt21064@gsk.com
|
|
pubmed:publicationType |
Journal Article
|
